Visugromab Biosimilar - Research Grade

Human

GDF15

>1mg/ml

Human IgG4 - kappa

CHO Cells

Ponsegromab Biosimilar - Research Grade (ICH5182)

https://www.imgt.org/mAb-DB/

ICH3002

Q99988

Blue ice

This product is a research-grade biosimilar of visugromab (development code CTL-002), supplied as an unconjugated, non-therapeutic analog built around the GDF15 target. It is a human IgG4-kappa molecule intended for research use only and is not a clinical drug. Visugromab is an investigational neutralizing antibody directed against GDF15 (growth differentiation factor 15), studied clinically as a monotherapy and in combination with anti-PD-1 checkpoint blockade in advanced, relapsed or refractory solid tumors, where high GDF15 in the tumor microenvironment is associated with immune evasion and cancer-associated cachexia. Because the antibody neutralizes soluble circulating GDF15, this reagent is well suited to functional and in-vitro work such as ligand-neutralization assays, blockade of GDF15-driven signaling, target-engagement and epitope studies, and as a defined isotype-matched comparator or positive control alongside other GDF15 tools. The material is manufactured to in-vivo research standards with low endotoxin and is offered in bulk milligram-to-gram quantities to support consistent, reproducible experiments across biology, characterization, and neutralization workflows. Lot-to-lot consistency supports longitudinal studies. GDF15 (growth differentiation factor 15; UniProt Q99988), also called MIC-1, NAG-1 or PLAB, is a distant, divergent member of the TGF-beta superfamily secreted as a disulfide-linked dimer. Circulating GDF15 rises during cellular stress, inflammation, aging, pregnancy, cardiometabolic disease and malignancy, making it a widely studied biomarker. Its principal characterized receptor is GFRAL (GDNF-family receptor alpha-like), whose expression is largely restricted to neurons of the area postrema and nucleus tractus solitarius in the hindbrain. GDF15 binding to GFRAL recruits the co-receptor RET, driving downstream AKT, ERK and PLC signaling that suppresses appetite and reduces body weight. In cancer, tumor-derived GDF15 contributes to cachexia and can dampen antitumor immunity, so neutralizing the ligand is being explored to restore checkpoint-inhibitor responsiveness and reverse wasting.

Macrophage inhibitory cytokine 1, MIC-1, NSAID-activated gene 1 protein, NAG-1, NSAID-regulated gene 1 protein, NRG-1, Placental TGF-beta, Placental bone morphogenetic protein, Prostate differentiation factor, Growth/differentiation factor 15, PDF, PLAB,

Detects human GDF15

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks